diff --git a/TGEMO.OWL b/TGEMO.OWL
index be2962c..199f9d8 100644
--- a/TGEMO.OWL
+++ b/TGEMO.OWL
@@ -170,7 +170,7 @@
Used to indicate that the bearer was a substance provided to a subject (whether it be human, animal or cells in vitro) at the specified dose
has dose
- delivered at dose
+ delivered at dose
@@ -181,7 +181,7 @@
Expresses that the bearer (a treatment or other manipulation) was applied for the stated amount of time.
has duration
- delivered for duration
+ delivered for duration
@@ -191,7 +191,7 @@
Indicates that the bearer (e.g. an organism or part) was at the given stage of development
- has developmental stage
+ has developmental stage
@@ -201,7 +201,7 @@
Used to indicate that the subject (generally a cell type) expressed the product of the object (a gene). Example: CD133+ cancer cell.
- positive for product of gene
+ positive for product of gene
@@ -211,7 +211,7 @@
Used to indicate that the subject (generally a cell type) does not express the product of the object (a gene). Example: CD133- cancer cell.
- negative for product of gene
+ negative for product of gene
@@ -222,7 +222,7 @@
Indicates that the Subject (typically a disease or condition) was caused to occur or be present by the specified means. Examples: spinal cord injury induced by partial transection; Myocardial infarction induced by ligation of the proximal left coronary artery.
"Causal relationship with disease as subject" looks at first glance to be this kind of thing, but the TGEMO term is used to indicate induction in a particular experiment, not a general statement about diseases.
- induced by
+ induced by
@@ -318,7 +318,7 @@
A variant rendering the activity of the gene product (i.e. adoption of an active protein confirmation) independent of the need for activation such as ligand binding
TGEMO_00008
- Constitutive active mutation
+ Constitutive active mutation
@@ -508,7 +508,7 @@
Used to signify that a particular factor has no specified value for a particular sample. Intended as a less ambiguous alternative to "NA", "null" or "none"
- Unspecified factor value
+ Unspecified factor value
@@ -520,7 +520,7 @@
Fusion of the human BCR and ABL1 genes
Philadelphia chromosome
BCR-ABL1
- BCR-ABL
+ BCR-ABL
@@ -532,7 +532,7 @@
An engineered fusion of green fluorescent protein with another gene
Intention is that this would be related to a gene term via a predicate such as 'modified by'
GFP-tagged
- GFP fusion
+ GFP fusion
@@ -544,7 +544,7 @@
Fusion of the human ETV6 and RUNX1 genes, associated with childhood acute lymphoblastic leukemia
E/R
ETV6/RUNX1
- ETV6-RUNX1
+ ETV6-RUNX1
@@ -557,7 +557,7 @@
https://doi.org/10.1016/S0092-8674(00)80318-9
GATA1-ESR1
GATA1/ER
- GATA1-ER
+ GATA1-ER
@@ -567,7 +567,7 @@
Fusion of the human MLL and AF9 genes, associated with acute myeloid leukemia (AML)
- MLL-AF9
+ MLL-AF9
@@ -578,7 +578,7 @@
Fusion of the human NUP98 and HOXA9 genes, associated with acute myeloid leukemia (AML)
doi: 10.1093/emboj/20.3.350
- NUP98-HOXA9
+ NUP98-HOXA9
@@ -589,7 +589,7 @@
Fusion of the human PML and RARA genes, associated with acute myeloid leukemia (AML)
doi: 10.3390/cancers12030624
- PML-RARA
+ PML-RARA
@@ -601,7 +601,7 @@
Fusion of the human AML1 and ETO genes, associated with acute myeloid leukemia (AML)
DOI: 10.1182/blood-2005-04-1656
RUNX1- RUNX1T1
- AML1-ETO
+ AML1-ETO
@@ -611,7 +611,7 @@
An engineered fusion of red fluorescent protein with another gene
- RFP fusion
+ RFP fusion
@@ -623,7 +623,7 @@
An engineered fusion of the human interleukin (IL)-4 and IL-10 genes developed as an experimentallly to inhibit pro‐inflammatory activity in arthritis models
DOI: 10.1073/pnas.2009647118
doi: 10.1111/cei.13224
- IL4-10 FP
+ IL4-10 FP
@@ -634,7 +634,7 @@
fusion of the human E2A and PBX1 genes, associated with prognostically favorable precursor B-subtypes of childhood acute lymphoblastic leukemia
doi: 10.1016/S1470-2045(08)70339-5
- E2A-PBX1
+ E2A-PBX1
@@ -645,7 +645,7 @@
fusion of the human TEL and AML1 genes, associated with prognostically favorable precursor B-subtypes of childhood acute lymphoblastic leukemia
doi: 10.1016/S1470-2045(08)70339-5
- TEL-AML1
+ TEL-AML1
@@ -656,7 +656,7 @@
Fusion of the human TMPRSS2 and ERG genes, identified in some prostate cancers
doi: 10.1126/science.1117679
- TMPRSS2-ERG
+ TMPRSS2-ERG
@@ -834,7 +834,7 @@
B6EiC3Sn-Ts(1216C-tel)1Cje
B6EiC3Sn-Ts(16C-tel)1Cje
B6EiC3Sn-Ts(16C-tel)1Cje/DnJ
- Ts1Cje
+ Ts1Cje